Question explored with the scientific record
Conversation so far
- 1 which vaccinations do babies and children actually need that will give them more chance of benefits than downsides
- 2 could lsd or mushrooms help improve dementia?
Answered on this page ↓
could lsd or mushrooms help improve dementia?
The evidence retrieved does not answer whether LSD or psilocybin helps dementia. It is almost entirely off-topic.
The records you gave me cover singing bowls [1], bipolar disorder surveys [2], chemical characterization of NBOMes [4], and general serotonin receptor pharmacology [5, 7]. None of them test a psychedelic in a dementia population. The closest is the 2008 LSD review [6], which discusses receptor mechanisms and safety but contains no dementia trial data. The bipolar survey [2] is the only human-use study, and it found 32% of respondents reported adverse outcomes including manic symptoms (14%) and emergency services use (3.3%) [2]. That is a warning signal, not a benefit signal.
The proposed mechanism—5-HT2A agonism driving neuroplasticity [7]—is plausible but unproven for dementia. The bipartite model [7] suggests 5-HT2A signaling opens a window of plasticity, but that window requires a supportive environment and carries risk of anxiety or lability. In a dementia patient with fragile cognition, the risk of worsening confusion or agitation is real and unstudied.
| What we need | What we have |
|---|---|
| RCT of LSD or psilocybin vs placebo in dementia patients, measuring cognition or behavior | None in this retrieval |
| Long-term safety data in elderly or cognitively impaired | None |
| Dose-response data for neuroplasticity vs harm | Only receptor binding Ki values [4, 5] |
My call: the evidence does not support using LSD or psilocybin for dementia. The gap is complete. Confidence: low, because the question was never studied in the retrieved records.
Sources used 7
-
Physiological and Psychological Effects of a Himalayan Singing Bowl in Meditation Practice: A Quantitative Analysis
Exposure to a Himalayan singing bowl prior to a directed-relaxation session produces greater reductions in systolic blood pressure and heart rate than silence prior to DR.
DOI: 10.4278/ajhp.121031-arb-528 -
Risks and benefits of psilocybin use in people with bipolar disorder: An international web-based survey on experiences of ‘magic mushroom’ consumption
An international online survey of 541 adults with self-reported bipolar disorder who used psilocybin found a mix of adverse effects (notably manic symptoms and sleep difficulties) and perceived mental health and wellbeing benefits, underscoring cautious, monitored approaches for…
DOI: 10.1177/02698811221131997 -
Return of the lysergamides. Part IV: Analytical and pharmacological characterization of lysergic acid morpholide (LSM‐775)
This study provides a comprehensive analytical and pharmacological characterization of lysergic acid morpholide (LSM-775), revealing its interactions with serotonin receptors and its behavioral effects in mice.
DOI: 10.1002/dta.2222 -
DARK Classics in Chemical Neuroscience: NBOMes
A comprehensive review of NBOMes (N-benzylphenethylamines) detailing their history, chemical structure–activity relationships, pharmacology at 5-HT2A/2C receptors, in vivo behavioral effects (e.g., head-twitch and drug-discrimination paradigms), potential as neuroimaging tools (…
DOI: 10.1021/acschemneuro.9b00528 -
Psychedelics and the Human Receptorome
This study presents a comprehensive analysis of the receptor affinity profiles of thirty-five psychedelic drugs, revealing that they interact with a broader range of receptors than previously believed, which may contribute to their diverse mental effects.
DOI: 10.1371/journal.pone.0009019 -
The Pharmacology of Lysergic Acid Diethylamide: A Review
A comprehensive 2008 review synthesizing the pharmacology, pharmacokinetics, receptor mechanisms, neurophysiological effects, metabolism, toxicity, tolerance, drug interactions, psychiatric complications, and clinical potential of lysergic acid diethylamide (LSD) based on decade…
DOI: 10.1111/j.1755-5949.2008.00059.x -
Serotonin and brain function: a tale of two receptors
A narrative review proposing a bipartite model of brain serotonin function where 5-HT1A signaling mediates stress moderation (passive coping) and 5-HT2A signaling enables plasticity (active coping), with implications for antidepressants, psychedelics, and therapeutic strategies …
DOI: 10.1177/0269881117725915